David Ledbetter is chief clinical officer of Dascena, a personalized medicine company.
David Ledbetter
Chief clinical officer
Dascena
From this contributor
There are no autism-specific genes, just brain genes
There is not yet a single example of a gene that, when mutated, increases the likelihood of autism but not of other neurodevelopmental conditions, including intellectual disability.
There are no autism-specific genes, just brain genes
By
David Ledbetter, Scott Myers
23 March 2021 | 5 min read
Developmental disorders should be viewed as continuum
Intellectual disability, autism, epilepsy and schizophrenia should be considered part of a spectrum of developmental brain dysfunction, says David Ledbetter.
Developmental disorders should be viewed as continuum
By
David Ledbetter
6 May 2013 | 3 min read
Explore more from The Transmitter
Scientists push back against stricter European Research Council grant application rules
In an open letter, scientists call the ERC’s suggestion to block grant reapplications for an additional year “at odds with scientific excellence.”
Scientists push back against stricter European Research Council grant application rules
In an open letter, scientists call the ERC’s suggestion to block grant reapplications for an additional year “at odds with scientific excellence.”
By
Lauren Schenkman
29 April 2026 | 5 min read
New study questions role of persistent gene activity in memory maintenance
An experiment in sea slugs suggests transcriptional changes might fade after 24 hours.
New study questions role of persistent gene activity in memory maintenance
An experiment in sea slugs suggests transcriptional changes might fade after 24 hours.
By
Siddhant Pusdekar
28 April 2026 | 4 min read
Tracking health in autistic adults, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 27 April.
Tracking health in autistic adults, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 27 April.
By
Jill Adams
28 April 2026 | 2 min read